DaVita Inc. (NYSE: DVA) Stock Competitors & Peer Comparison
See DVA's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Medical - Care Facilities Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for DVA and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DVA | $182.00 | +1.08% | 11.7B | 14.30 | $12.80 | N/A |
| HCA | $419.53 | +4.36% | 91.3B | 14.57 | $28.96 | +0.71% |
| THC | $264.38 | +2.05% | 21.7B | 15.61 | $17.24 | N/A |
| EHC | $120.71 | +0.20% | 12.1B | 20.82 | $5.84 | +0.63% |
| FMS | $22.33 | -0.53% | 12B | 8.39 | $2.66 | +3.87% |
| UHS | $171.97 | +0.04% | 10.6B | 7.80 | $22.54 | +0.45% |
| ENSG | $172.05 | +0.88% | 10B | 24.89 | $6.90 | +0.15% |
| OSH | $39.00 | +0.08% | 9.5B | -17.65 | -$2.21 | N/A |
| PACS | $44.49 | +1.87% | 7.1B | 23.59 | $1.89 | N/A |
| CHE | $510.02 | -1.73% | 6.8B | 24.00 | $21.61 | +0.49% |
Stock Comparison
HCA Healthcare, Inc. (NYSE: HCA)
DVA vs HCA Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, HCA has a market cap of 91.3B. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while HCA trades at $419.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas HCA's P/E ratio is 14.57. In terms of profitability, DVA's ROE is -1.24%, compared to HCA's ROE of -1.13%. Regarding short-term risk, DVA is less volatile compared to HCA. This indicates lower risk in terms of short-term price fluctuations for DVA.Check HCA's competition here
Tenet Healthcare Corporation (NYSE: THC)
DVA vs THC Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, THC has a market cap of 21.7B. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while THC trades at $264.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas THC's P/E ratio is 15.61. In terms of profitability, DVA's ROE is -1.24%, compared to THC's ROE of +0.51%. Regarding short-term risk, DVA is less volatile compared to THC. This indicates lower risk in terms of short-term price fluctuations for DVA.Check THC's competition here
Encompass Health Corporation (NYSE: EHC)
DVA vs EHC Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, EHC has a market cap of 12.1B. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while EHC trades at $120.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas EHC's P/E ratio is 20.82. In terms of profitability, DVA's ROE is -1.24%, compared to EHC's ROE of +0.25%. Regarding short-term risk, DVA is less volatile compared to EHC. This indicates lower risk in terms of short-term price fluctuations for DVA.Check EHC's competition here
Fresenius Medical Care AG & Co. KGaA (NYSE: FMS)
DVA vs FMS Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, FMS has a market cap of 12B. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while FMS trades at $22.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas FMS's P/E ratio is 8.39. In terms of profitability, DVA's ROE is -1.24%, compared to FMS's ROE of +0.07%. Regarding short-term risk, DVA is more volatile compared to FMS. This indicates higher risk in terms of short-term price fluctuations for DVA.Check FMS's competition here
Universal Health Services, Inc. (NYSE: UHS)
DVA vs UHS Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, UHS has a market cap of 10.6B. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while UHS trades at $171.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas UHS's P/E ratio is 7.80. In terms of profitability, DVA's ROE is -1.24%, compared to UHS's ROE of +0.21%. Regarding short-term risk, DVA is less volatile compared to UHS. This indicates lower risk in terms of short-term price fluctuations for DVA.Check UHS's competition here
The Ensign Group, Inc. (NASDAQ: ENSG)
DVA vs ENSG Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, ENSG has a market cap of 10B. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while ENSG trades at $172.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas ENSG's P/E ratio is 24.89. In terms of profitability, DVA's ROE is -1.24%, compared to ENSG's ROE of +0.17%. Regarding short-term risk, DVA is more volatile compared to ENSG. This indicates higher risk in terms of short-term price fluctuations for DVA.Check ENSG's competition here
Oak Street Health, Inc. (NYSE: OSH)
DVA vs OSH Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, OSH has a market cap of 9.5B. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while OSH trades at $39.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas OSH's P/E ratio is -17.65. In terms of profitability, DVA's ROE is -1.24%, compared to OSH's ROE of +4.64%. Regarding short-term risk, DVA is more volatile compared to OSH. This indicates higher risk in terms of short-term price fluctuations for DVA.Check OSH's competition here
PACS Group, Inc. (NYSE: PACS)
DVA vs PACS Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, PACS has a market cap of 7.1B. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while PACS trades at $44.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas PACS's P/E ratio is 23.59. In terms of profitability, DVA's ROE is -1.24%, compared to PACS's ROE of +0.27%. Regarding short-term risk, DVA is less volatile compared to PACS. This indicates lower risk in terms of short-term price fluctuations for DVA.Check PACS's competition here
Chemed Corporation (NYSE: CHE)
DVA vs CHE Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, CHE has a market cap of 6.8B. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while CHE trades at $510.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas CHE's P/E ratio is 24.00. In terms of profitability, DVA's ROE is -1.24%, compared to CHE's ROE of +0.29%. Regarding short-term risk, DVA is less volatile compared to CHE. This indicates lower risk in terms of short-term price fluctuations for DVA.Check CHE's competition here
Hims & Hers Health, Inc. (NYSE: HIMS)
DVA vs HIMS Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, HIMS has a market cap of 6.2B. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while HIMS trades at $27.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas HIMS's P/E ratio is -43.62. In terms of profitability, DVA's ROE is -1.24%, compared to HIMS's ROE of -0.30%. Regarding short-term risk, DVA is less volatile compared to HIMS. This indicates lower risk in terms of short-term price fluctuations for DVA.Check HIMS's competition here
LHC Group, Inc. (NASDAQ: LHCG)
DVA vs LHCG Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, LHCG has a market cap of 5.3B. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while LHCG trades at $169.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas LHCG's P/E ratio is 82.83. In terms of profitability, DVA's ROE is -1.24%, compared to LHCG's ROE of +0.04%. Regarding short-term risk, DVA is more volatile compared to LHCG. This indicates higher risk in terms of short-term price fluctuations for DVA.Check LHCG's competition here
LifeStance Health Group, Inc. (NASDAQ: LFST)
DVA vs LFST Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, LFST has a market cap of 4.9B. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while LFST trades at $13.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas LFST's P/E ratio is 95.05. In terms of profitability, DVA's ROE is -1.24%, compared to LFST's ROE of +0.03%. Regarding short-term risk, DVA is less volatile compared to LFST. This indicates lower risk in terms of short-term price fluctuations for DVA.Check LFST's competition here
Concentra Group Holdings Parent, Inc. (NYSE: CON)
DVA vs CON Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, CON has a market cap of 4.4B. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while CON trades at $34.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas CON's P/E ratio is 21.50. In terms of profitability, DVA's ROE is -1.24%, compared to CON's ROE of +0.47%. Regarding short-term risk, DVA is more volatile compared to CON. This indicates higher risk in terms of short-term price fluctuations for DVA.Check CON's competition here
National HealthCare Corporation (AMEX: NHC)
DVA vs NHC Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, NHC has a market cap of 3.6B. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while NHC trades at $224.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas NHC's P/E ratio is 29.09. In terms of profitability, DVA's ROE is -1.24%, compared to NHC's ROE of +0.13%. Regarding short-term risk, DVA is less volatile compared to NHC. This indicates lower risk in terms of short-term price fluctuations for DVA.Check NHC's competition here
Option Care Health, Inc. (NASDAQ: OPCH)
DVA vs OPCH Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, OPCH has a market cap of 3.5B. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while OPCH trades at $23.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas OPCH's P/E ratio is 13.74. In terms of profitability, DVA's ROE is -1.24%, compared to OPCH's ROE of +0.16%. Regarding short-term risk, DVA is more volatile compared to OPCH. This indicates higher risk in terms of short-term price fluctuations for DVA.Check OPCH's competition here
Amedisys, Inc. (NASDAQ: AMED)
DVA vs AMED Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, AMED has a market cap of 3.3B. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while AMED trades at $100.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas AMED's P/E ratio is 39.30. In terms of profitability, DVA's ROE is -1.24%, compared to AMED's ROE of +0.11%. Regarding short-term risk, DVA is more volatile compared to AMED. This indicates higher risk in terms of short-term price fluctuations for DVA.Check AMED's competition here
Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH)
DVA vs AVAH Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, AVAH has a market cap of 3.1B. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while AVAH trades at $13.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas AVAH's P/E ratio is 20.62. In terms of profitability, DVA's ROE is -1.24%, compared to AVAH's ROE of +1.50%. Regarding short-term risk, DVA is more volatile compared to AVAH. This indicates higher risk in terms of short-term price fluctuations for DVA.Check AVAH's competition here
Brookdale Senior Living Inc. (NYSE: BKD)
DVA vs BKD Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, BKD has a market cap of 2.9B. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while BKD trades at $12.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas BKD's P/E ratio is -20.94. In terms of profitability, DVA's ROE is -1.24%, compared to BKD's ROE of +4.06%. Regarding short-term risk, DVA is less volatile compared to BKD. This indicates lower risk in terms of short-term price fluctuations for DVA.Check BKD's competition here
Guardian Pharmacy Services, Inc. (NYSE: GRDN)
DVA vs GRDN Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, GRDN has a market cap of 2.7B. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while GRDN trades at $42.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas GRDN's P/E ratio is 38.03. In terms of profitability, DVA's ROE is -1.24%, compared to GRDN's ROE of +0.31%. Regarding short-term risk, DVA is less volatile compared to GRDN. This indicates lower risk in terms of short-term price fluctuations for DVA.Check GRDN's competition here
Acadia Healthcare Company, Inc. (NASDAQ: ACHC)
DVA vs ACHC Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, ACHC has a market cap of 2.6B. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while ACHC trades at $28.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas ACHC's P/E ratio is 14.17. In terms of profitability, DVA's ROE is -1.24%, compared to ACHC's ROE of -0.50%. Regarding short-term risk, DVA is less volatile compared to ACHC. This indicates lower risk in terms of short-term price fluctuations for DVA.Check ACHC's competition here
Addus HomeCare Corporation (NASDAQ: ADUS)
DVA vs ADUS Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, ADUS has a market cap of 2.2B. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while ADUS trades at $117.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas ADUS's P/E ratio is 17.85. In terms of profitability, DVA's ROE is -1.24%, compared to ADUS's ROE of +0.10%. Regarding short-term risk, DVA is less volatile compared to ADUS. This indicates lower risk in terms of short-term price fluctuations for DVA.Check ADUS's competition here
Pediatrix Medical Group, Inc. (NYSE: MD)
DVA vs MD Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, MD has a market cap of 2.2B. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while MD trades at $27.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas MD's P/E ratio is 12.09. In terms of profitability, DVA's ROE is -1.24%, compared to MD's ROE of +0.20%. Regarding short-term risk, DVA is less volatile compared to MD. This indicates lower risk in terms of short-term price fluctuations for DVA.Check MD's competition here
Select Medical Holdings Corporation (NYSE: SEM)
DVA vs SEM Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, SEM has a market cap of 2B. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while SEM trades at $16.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas SEM's P/E ratio is 15.43. In terms of profitability, DVA's ROE is -1.24%, compared to SEM's ROE of +0.08%. Regarding short-term risk, DVA is more volatile compared to SEM. This indicates higher risk in terms of short-term price fluctuations for DVA.Check SEM's competition here
Astrana Health, Inc. (NASDAQ: ASTH)
DVA vs ASTH Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, ASTH has a market cap of 1.9B. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while ASTH trades at $38.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas ASTH's P/E ratio is 45.86. In terms of profitability, DVA's ROE is -1.24%, compared to ASTH's ROE of +0.05%. Regarding short-term risk, DVA is less volatile compared to ASTH. This indicates lower risk in terms of short-term price fluctuations for DVA.Check ASTH's competition here
Sonida Senior Living, Inc. (NYSE: SNDA)
DVA vs SNDA Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, SNDA has a market cap of 1.9B. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while SNDA trades at $39.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas SNDA's P/E ratio is -6.39. In terms of profitability, DVA's ROE is -1.24%, compared to SNDA's ROE of -0.26%. Regarding short-term risk, DVA is less volatile compared to SNDA. This indicates lower risk in terms of short-term price fluctuations for DVA.Check SNDA's competition here
Surgery Partners, Inc. (NASDAQ: SGRY)
DVA vs SGRY Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, SGRY has a market cap of 1.8B. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while SGRY trades at $14.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas SGRY's P/E ratio is 36.21. In terms of profitability, DVA's ROE is -1.24%, compared to SGRY's ROE of -0.05%. Regarding short-term risk, DVA is less volatile compared to SGRY. This indicates lower risk in terms of short-term price fluctuations for DVA.Check SGRY's competition here
Apollo Medical Holdings, Inc. (NASDAQ: AMEH)
DVA vs AMEH Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, AMEH has a market cap of 1.8B. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while AMEH trades at $40.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas AMEH's P/E ratio is 39.25. In terms of profitability, DVA's ROE is -1.24%, compared to AMEH's ROE of +0.05%. Regarding short-term risk, DVA is less volatile compared to AMEH. This indicates lower risk in terms of short-term price fluctuations for DVA.Check AMEH's competition here
Ardent Health Inc. (NYSE: ARDT)
DVA vs ARDT Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, ARDT has a market cap of 1.6B. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while ARDT trades at $10.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas ARDT's P/E ratio is 8.98. In terms of profitability, DVA's ROE is -1.24%, compared to ARDT's ROE of +0.05%. Regarding short-term risk, DVA is less volatile compared to ARDT. This indicates lower risk in terms of short-term price fluctuations for DVA.Check ARDT's competition here
Agilon Health, Inc. (NYSE: AGL)
DVA vs AGL Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, AGL has a market cap of 1.6B. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while AGL trades at $94.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas AGL's P/E ratio is -6.09. In terms of profitability, DVA's ROE is -1.24%, compared to AGL's ROE of -1.19%. Regarding short-term risk, DVA is less volatile compared to AGL. This indicates lower risk in terms of short-term price fluctuations for DVA.Check AGL's competition here
Healthcare Services Group, Inc. (NASDAQ: HCSG)
DVA vs HCSG Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, HCSG has a market cap of 1.5B. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while HCSG trades at $21.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas HCSG's P/E ratio is 17.62. In terms of profitability, DVA's ROE is -1.24%, compared to HCSG's ROE of +0.24%. Regarding short-term risk, DVA is less volatile compared to HCSG. This indicates lower risk in terms of short-term price fluctuations for DVA.Check HCSG's competition here
Innovage Holding Corp. (NASDAQ: INNV)
DVA vs INNV Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, INNV has a market cap of 1.5B. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while INNV trades at $10.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas INNV's P/E ratio is -122.56. In terms of profitability, DVA's ROE is -1.24%, compared to INNV's ROE of -0.01%. Regarding short-term risk, DVA is less volatile compared to INNV. This indicates lower risk in terms of short-term price fluctuations for DVA.Check INNV's competition here
The Pennant Group, Inc. (NASDAQ: PNTG)
DVA vs PNTG Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, PNTG has a market cap of 1.4B. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while PNTG trades at $39.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas PNTG's P/E ratio is 30.00. In terms of profitability, DVA's ROE is -1.24%, compared to PNTG's ROE of +0.10%. Regarding short-term risk, DVA is less volatile compared to PNTG. This indicates lower risk in terms of short-term price fluctuations for DVA.Check PNTG's competition here
Nutex Health, Inc. (NASDAQ: NUTX)
DVA vs NUTX Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, NUTX has a market cap of 1.4B. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while NUTX trades at $196.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas NUTX's P/E ratio is 7.82. In terms of profitability, DVA's ROE is -1.24%, compared to NUTX's ROE of +0.52%. Regarding short-term risk, DVA is less volatile compared to NUTX. This indicates lower risk in terms of short-term price fluctuations for DVA.Check NUTX's competition here
AMN Healthcare Services, Inc. (NYSE: AMN)
DVA vs AMN Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, AMN has a market cap of 1.3B. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while AMN trades at $33.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas AMN's P/E ratio is 11.41. In terms of profitability, DVA's ROE is -1.24%, compared to AMN's ROE of +0.15%. Regarding short-term risk, DVA is less volatile compared to AMN. This indicates lower risk in terms of short-term price fluctuations for DVA.Check AMN's competition here
Brookdale Senior Living Inc. 7. (NYSE: BKDT)
DVA vs BKDT Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, BKDT has a market cap of 1.2B. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while BKDT trades at $77.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas BKDT's P/E ratio is N/A. In terms of profitability, DVA's ROE is -1.24%, compared to BKDT's ROE of +4.06%. Regarding short-term risk, DVA is more volatile compared to BKDT. This indicates higher risk in terms of short-term price fluctuations for DVA.Check BKDT's competition here
U.S. Physical Therapy, Inc. (NYSE: USPH)
DVA vs USPH Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, USPH has a market cap of 1.2B. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while USPH trades at $77.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas USPH's P/E ratio is 30.60. In terms of profitability, DVA's ROE is -1.24%, compared to USPH's ROE of -0.01%. Regarding short-term risk, DVA is less volatile compared to USPH. This indicates lower risk in terms of short-term price fluctuations for DVA.Check USPH's competition here
Talkspace, Inc. (NASDAQ: TALK)
DVA vs TALK Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, TALK has a market cap of 879.4M. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while TALK trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas TALK's P/E ratio is 774.34. In terms of profitability, DVA's ROE is -1.24%, compared to TALK's ROE of +0.00%. Regarding short-term risk, DVA is more volatile compared to TALK. This indicates higher risk in terms of short-term price fluctuations for DVA.Check TALK's competition here
GMR Solutions Inc. (NYSE: GMRS)
DVA vs GMRS Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, GMRS has a market cap of 707.8M. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while GMRS trades at $12.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas GMRS's P/E ratio is 5.82. In terms of profitability, DVA's ROE is -1.24%, compared to GMRS's ROE of +0.16%. Regarding short-term risk, DVA is less volatile compared to GMRS. This indicates lower risk in terms of short-term price fluctuations for DVA.Check GMRS's competition here
Enhabit, Inc. (NYSE: EHAB)
DVA vs EHAB Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, EHAB has a market cap of 706.9M. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while EHAB trades at $13.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas EHAB's P/E ratio is -197.14. In terms of profitability, DVA's ROE is -1.24%, compared to EHAB's ROE of -0.01%. Regarding short-term risk, DVA is more volatile compared to EHAB. This indicates higher risk in terms of short-term price fluctuations for DVA.Check EHAB's competition here
Starling Oncology, Inc. (NASDAQ: STLN)
DVA vs STLN Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, STLN has a market cap of 628.9M. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while STLN trades at $6.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas STLN's P/E ratio is N/A. In terms of profitability, DVA's ROE is -1.24%, compared to STLN's ROE of +2.10%. Regarding short-term risk, DVA is less volatile compared to STLN. This indicates lower risk in terms of short-term price fluctuations for DVA.Check STLN's competition here
The Oncology Institute, Inc. (NASDAQ: TOI)
DVA vs TOI Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, TOI has a market cap of 512.9M. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while TOI trades at $5.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas TOI's P/E ratio is -14.25. In terms of profitability, DVA's ROE is -1.24%, compared to TOI's ROE of +2.10%. Regarding short-term risk, DVA is less volatile compared to TOI. This indicates lower risk in terms of short-term price fluctuations for DVA.Check TOI's competition here
Strata Critical Medical, Inc. (NASDAQ: SRTA)
DVA vs SRTA Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, SRTA has a market cap of 451.7M. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while SRTA trades at $5.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas SRTA's P/E ratio is -24.61. In terms of profitability, DVA's ROE is -1.24%, compared to SRTA's ROE of +0.14%. Regarding short-term risk, DVA is less volatile compared to SRTA. This indicates lower risk in terms of short-term price fluctuations for DVA.Check SRTA's competition here
Charming Medical Limited Class A Ordinary Shares (NASDAQ: MCTA)
DVA vs MCTA Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, MCTA has a market cap of 445.6M. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while MCTA trades at $29.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas MCTA's P/E ratio is 419.36. In terms of profitability, DVA's ROE is -1.24%, compared to MCTA's ROE of -2.33%. Regarding short-term risk, DVA is more volatile compared to MCTA. This indicates higher risk in terms of short-term price fluctuations for DVA.Check MCTA's competition here
Community Health Systems, Inc. (NYSE: CYH)
DVA vs CYH Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, CYH has a market cap of 414.6M. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while CYH trades at $2.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas CYH's P/E ratio is 4.03. In terms of profitability, DVA's ROE is -1.24%, compared to CYH's ROE of +0.21%. Regarding short-term risk, DVA is less volatile compared to CYH. This indicates lower risk in terms of short-term price fluctuations for DVA.Check CYH's competition here
Auna S.A. (NYSE: AUNA)
DVA vs AUNA Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, AUNA has a market cap of 384.2M. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while AUNA trades at $5.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas AUNA's P/E ratio is 4.68. In terms of profitability, DVA's ROE is -1.24%, compared to AUNA's ROE of +0.01%. Regarding short-term risk, DVA is more volatile compared to AUNA. This indicates higher risk in terms of short-term price fluctuations for DVA.Check AUNA's competition here
Viemed Healthcare, Inc. (NASDAQ: VMD)
DVA vs VMD Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, VMD has a market cap of 333.7M. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while VMD trades at $8.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas VMD's P/E ratio is 24.33. In terms of profitability, DVA's ROE is -1.24%, compared to VMD's ROE of +0.10%. Regarding short-term risk, DVA is more volatile compared to VMD. This indicates higher risk in terms of short-term price fluctuations for DVA.Check VMD's competition here
Capital Senior Living Corporation (NYSE: CSU)
DVA vs CSU Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, CSU has a market cap of 223.7M. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while CSU trades at $33.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas CSU's P/E ratio is 0.67. In terms of profitability, DVA's ROE is -1.24%, compared to CSU's ROE of -0.33%. Regarding short-term risk, DVA is less volatile compared to CSU. This indicates lower risk in terms of short-term price fluctuations for DVA.Check CSU's competition here
AirSculpt Technologies, Inc. (NASDAQ: AIRS)
DVA vs AIRS Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, AIRS has a market cap of 184.1M. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while AIRS trades at $2.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas AIRS's P/E ratio is -87.00. In terms of profitability, DVA's ROE is -1.24%, compared to AIRS's ROE of -0.13%. Regarding short-term risk, DVA is less volatile compared to AIRS. This indicates lower risk in terms of short-term price fluctuations for DVA.Check AIRS's competition here
The Joint Corp. (NASDAQ: JYNT)
DVA vs JYNT Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, JYNT has a market cap of 115.3M. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while JYNT trades at $8.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas JYNT's P/E ratio is 80.90. In terms of profitability, DVA's ROE is -1.24%, compared to JYNT's ROE of +0.22%. Regarding short-term risk, DVA is less volatile compared to JYNT. This indicates lower risk in terms of short-term price fluctuations for DVA.Check JYNT's competition here
Five Star Senior Living Inc. (NASDAQ: FVE)
DVA vs FVE Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, FVE has a market cap of 98.4M. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while FVE trades at $2.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas FVE's P/E ratio is -5.64. In terms of profitability, DVA's ROE is -1.24%, compared to FVE's ROE of -0.15%. Regarding short-term risk, DVA is less volatile compared to FVE. This indicates lower risk in terms of short-term price fluctuations for DVA.Check FVE's competition here
Kindly MD, Inc. (NASDAQ: KDLYW)
DVA vs KDLYW Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, KDLYW has a market cap of 96.5M. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while KDLYW trades at $18.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas KDLYW's P/E ratio is N/A. In terms of profitability, DVA's ROE is -1.24%, compared to KDLYW's ROE of -1.05%. Regarding short-term risk, DVA is less volatile compared to KDLYW. This indicates lower risk in terms of short-term price fluctuations for DVA.Check KDLYW's competition here
Park Dental Partners, Inc. Common Stock (NASDAQ: PARK)
DVA vs PARK Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, PARK has a market cap of 94.7M. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while PARK trades at $20.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas PARK's P/E ratio is 28.35. In terms of profitability, DVA's ROE is -1.24%, compared to PARK's ROE of -0.18%. Regarding short-term risk, DVA is less volatile compared to PARK. This indicates lower risk in terms of short-term price fluctuations for DVA.Check PARK's competition here
biote Corp. (NASDAQ: BTMD)
DVA vs BTMD Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, BTMD has a market cap of 64M. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while BTMD trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas BTMD's P/E ratio is 13.18. In terms of profitability, DVA's ROE is -1.24%, compared to BTMD's ROE of -0.09%. Regarding short-term risk, DVA is less volatile compared to BTMD. This indicates lower risk in terms of short-term price fluctuations for DVA.Check BTMD's competition here
AlerisLife Inc. (NASDAQ: ALR)
DVA vs ALR Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, ALR has a market cap of 44.2M. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while ALR trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas ALR's P/E ratio is -1.11. In terms of profitability, DVA's ROE is -1.24%, compared to ALR's ROE of -0.15%. Regarding short-term risk, DVA is more volatile compared to ALR. This indicates higher risk in terms of short-term price fluctuations for DVA.Check ALR's competition here
DocGo Inc. (NASDAQ: DCGO)
DVA vs DCGO Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, DCGO has a market cap of 36.5M. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while DCGO trades at $0.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas DCGO's P/E ratio is -0.20. In terms of profitability, DVA's ROE is -1.24%, compared to DCGO's ROE of -1.16%. Regarding short-term risk, DVA is less volatile compared to DCGO. This indicates lower risk in terms of short-term price fluctuations for DVA.Check DCGO's competition here
Cryo-Cell International, Inc. (AMEX: CCEL)
DVA vs CCEL Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, CCEL has a market cap of 33.1M. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while CCEL trades at $4.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas CCEL's P/E ratio is -13.70. In terms of profitability, DVA's ROE is -1.24%, compared to CCEL's ROE of +0.14%. Regarding short-term risk, DVA is more volatile compared to CCEL. This indicates higher risk in terms of short-term price fluctuations for DVA.Check CCEL's competition here
IMAC Holdings, Inc. (NASDAQ: IMAC)
DVA vs IMAC Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, IMAC has a market cap of 33.1M. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while IMAC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas IMAC's P/E ratio is -2.27. In terms of profitability, DVA's ROE is -1.24%, compared to IMAC's ROE of +0.00%. Regarding short-term risk, DVA is less volatile compared to IMAC. This indicates lower risk in terms of short-term price fluctuations for DVA.Check IMAC's competition here
P3 Health Partners Inc. (NASDAQ: PIII)
DVA vs PIII Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, PIII has a market cap of 28.2M. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while PIII trades at $8.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas PIII's P/E ratio is -0.26. In terms of profitability, DVA's ROE is -1.24%, compared to PIII's ROE of +1.61%. Regarding short-term risk, DVA is less volatile compared to PIII. This indicates lower risk in terms of short-term price fluctuations for DVA.Check PIII's competition here
EUDA Health Holdings Limited (NASDAQ: EUDA)
DVA vs EUDA Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, EUDA has a market cap of 24.5M. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while EUDA trades at $12.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas EUDA's P/E ratio is -24.74. In terms of profitability, DVA's ROE is -1.24%, compared to EUDA's ROE of +1.20%. Regarding short-term risk, DVA is less volatile compared to EUDA. This indicates lower risk in terms of short-term price fluctuations for DVA.Check EUDA's competition here
Cano Health, Inc. (NYSE: CANO-WT)
DVA vs CANO-WT Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, CANO-WT has a market cap of 19.3M. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while CANO-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas CANO-WT's P/E ratio is N/A. In terms of profitability, DVA's ROE is -1.24%, compared to CANO-WT's ROE of -1.49%. Regarding short-term risk, DVA is less volatile compared to CANO-WT. This indicates lower risk in terms of short-term price fluctuations for DVA.Check CANO-WT's competition here
Aesthetic Medical International Holdings Group Limited (NASDAQ: AIH)
DVA vs AIH Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, AIH has a market cap of 15.9M. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while AIH trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas AIH's P/E ratio is -2.78. In terms of profitability, DVA's ROE is -1.24%, compared to AIH's ROE of +1.16%. Regarding short-term risk, DVA is less volatile compared to AIH. This indicates lower risk in terms of short-term price fluctuations for DVA.Check AIH's competition here
P3 Health Partners Inc. (NASDAQ: PIIIW)
DVA vs PIIIW Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, PIIIW has a market cap of 14.9M. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while PIIIW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas PIIIW's P/E ratio is N/A. In terms of profitability, DVA's ROE is -1.24%, compared to PIIIW's ROE of +1.61%. Regarding short-term risk, DVA is less volatile compared to PIIIW. This indicates lower risk in terms of short-term price fluctuations for DVA.Check PIIIW's competition here
Cano Health, Inc. (NYSE: CANO)
DVA vs CANO Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, CANO has a market cap of 12.4M. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while CANO trades at $2.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas CANO's P/E ratio is -0.01. In terms of profitability, DVA's ROE is -1.24%, compared to CANO's ROE of -1.49%. Regarding short-term risk, DVA is less volatile compared to CANO. This indicates lower risk in terms of short-term price fluctuations for DVA.Check CANO's competition here
Avem Health Partners, Inc. (NYSE: FPCG)
DVA vs FPCG Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, FPCG has a market cap of 10.1M. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while FPCG trades at $1,025.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas FPCG's P/E ratio is 0.09. In terms of profitability, DVA's ROE is -1.24%, compared to FPCG's ROE of +0.00%. Regarding short-term risk, DVA is more volatile compared to FPCG. This indicates higher risk in terms of short-term price fluctuations for DVA.Check FPCG's competition here
American Shared Hospital Services (AMEX: AMS)
DVA vs AMS Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, AMS has a market cap of 9.9M. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while AMS trades at $1.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas AMS's P/E ratio is -5.90. In terms of profitability, DVA's ROE is -1.24%, compared to AMS's ROE of -0.07%. Regarding short-term risk, DVA is less volatile compared to AMS. This indicates lower risk in terms of short-term price fluctuations for DVA.Check AMS's competition here
Field Trip Health Ltd. (NASDAQ: FTRP)
DVA vs FTRP Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, FTRP has a market cap of 9.8M. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while FTRP trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas FTRP's P/E ratio is -1.22. In terms of profitability, DVA's ROE is -1.24%, compared to FTRP's ROE of -0.62%. Regarding short-term risk, DVA is less volatile compared to FTRP. This indicates lower risk in terms of short-term price fluctuations for DVA.Check FTRP's competition here
Basel Medical Group Ltd Ordinary Shares (NASDAQ: BMGL)
DVA vs BMGL Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, BMGL has a market cap of 7.3M. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while BMGL trades at $4.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas BMGL's P/E ratio is -0.88. In terms of profitability, DVA's ROE is -1.24%, compared to BMGL's ROE of -1.74%. Regarding short-term risk, DVA is less volatile compared to BMGL. This indicates lower risk in terms of short-term price fluctuations for DVA.Check BMGL's competition here
20/20 Biolabs Inc. (NASDAQ: AIDX)
DVA vs AIDX Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, AIDX has a market cap of 6.9M. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while AIDX trades at $0.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas AIDX's P/E ratio is -1.06. In terms of profitability, DVA's ROE is -1.24%, compared to AIDX's ROE of -3.87%. Regarding short-term risk, DVA is less volatile compared to AIDX. This indicates lower risk in terms of short-term price fluctuations for DVA.Check AIDX's competition here
ModivCare Inc. (NASDAQ: MODV)
DVA vs MODV Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, MODV has a market cap of 6.2M. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while MODV trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas MODV's P/E ratio is -0.03. In terms of profitability, DVA's ROE is -1.24%, compared to MODV's ROE of +1.36%. Regarding short-term risk, DVA is more volatile compared to MODV. This indicates higher risk in terms of short-term price fluctuations for DVA.Check MODV's competition here
Greenbrook TMS Inc. (NASDAQ: GBNH)
DVA vs GBNH Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, GBNH has a market cap of 5.5M. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while GBNH trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas GBNH's P/E ratio is -0.06. In terms of profitability, DVA's ROE is -1.24%, compared to GBNH's ROE of +15.74%. Regarding short-term risk, DVA is less volatile compared to GBNH. This indicates lower risk in terms of short-term price fluctuations for DVA.Check GBNH's competition here
Regional Health Properties, Inc. (AMEX: RHE)
DVA vs RHE Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, RHE has a market cap of 5.2M. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while RHE trades at $2.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas RHE's P/E ratio is -1.79. In terms of profitability, DVA's ROE is -1.24%, compared to RHE's ROE of -1.31%. Regarding short-term risk, DVA is less volatile compared to RHE. This indicates lower risk in terms of short-term price fluctuations for DVA.Check RHE's competition here
Regional Health Properties, Inc. (AMEX: RHE-PA)
DVA vs RHE-PA Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, RHE-PA has a market cap of 5.2M. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while RHE-PA trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas RHE-PA's P/E ratio is -0.09. In terms of profitability, DVA's ROE is -1.24%, compared to RHE-PA's ROE of +1.09%. Regarding short-term risk, DVA is less volatile compared to RHE-PA. This indicates lower risk in terms of short-term price fluctuations for DVA.Check RHE-PA's competition here
The Oncology Institute, Inc. (NASDAQ: TOIIW)
DVA vs TOIIW Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, TOIIW has a market cap of 4.7M. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while TOIIW trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas TOIIW's P/E ratio is -0.17. In terms of profitability, DVA's ROE is -1.24%, compared to TOIIW's ROE of +2.10%. Regarding short-term risk, DVA is more volatile compared to TOIIW. This indicates higher risk in terms of short-term price fluctuations for DVA.Check TOIIW's competition here
Starling Oncology Inc. Wt (NASDAQ: STLNW)
DVA vs STLNW Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, STLNW has a market cap of 4M. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while STLNW trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas STLNW's P/E ratio is -0.13. In terms of profitability, DVA's ROE is -1.24%, compared to STLNW's ROE of +2.10%. Regarding short-term risk, DVA is less volatile compared to STLNW. This indicates lower risk in terms of short-term price fluctuations for DVA.Check STLNW's competition here
IMAC Holdings, Inc. (NASDAQ: IMACW)
DVA vs IMACW Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, IMACW has a market cap of 1.7M. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while IMACW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas IMACW's P/E ratio is N/A. In terms of profitability, DVA's ROE is -1.24%, compared to IMACW's ROE of +0.73%. Regarding short-term risk, DVA is less volatile compared to IMACW. This indicates lower risk in terms of short-term price fluctuations for DVA.Check IMACW's competition here
Endovia Health Sciences, Inc. (AMEX: EDVA)
DVA vs EDVA Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, EDVA has a market cap of 1.6M. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while EDVA trades at $0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas EDVA's P/E ratio is N/A. In terms of profitability, DVA's ROE is -1.24%, compared to EDVA's ROE of N/A. Regarding short-term risk, DVA is less volatile compared to EDVA. This indicates lower risk in terms of short-term price fluctuations for DVA.Check EDVA's competition here
EUDA Health Holdings Limited (NASDAQ: EUDAW)
DVA vs EUDAW Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, EUDAW has a market cap of 1.1M. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while EUDAW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas EUDAW's P/E ratio is 0.04. In terms of profitability, DVA's ROE is -1.24%, compared to EUDAW's ROE of +1.20%. Regarding short-term risk, DVA is more volatile compared to EUDAW. This indicates higher risk in terms of short-term price fluctuations for DVA.Check EUDAW's competition here
Concord Medical Services Holdings Limited (NYSE: CCM)
DVA vs CCM Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, CCM has a market cap of 605.8K. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while CCM trades at $3.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas CCM's P/E ratio is -0.28. In terms of profitability, DVA's ROE is -1.24%, compared to CCM's ROE of +0.06%. Regarding short-term risk, DVA is less volatile compared to CCM. This indicates lower risk in terms of short-term price fluctuations for DVA.Check CCM's competition here
NewGenIvf Group Limited (NASDAQ: NIVF)
DVA vs NIVF Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, NIVF has a market cap of 72K. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while NIVF trades at $1.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas NIVF's P/E ratio is 0.56. In terms of profitability, DVA's ROE is -1.24%, compared to NIVF's ROE of +0.33%. Regarding short-term risk, DVA is less volatile compared to NIVF. This indicates lower risk in terms of short-term price fluctuations for DVA.Check NIVF's competition here
NewGenIvf Group Limited (NASDAQ: NIVFW)
DVA vs NIVFW Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, NIVFW has a market cap of 43.2K. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while NIVFW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas NIVFW's P/E ratio is -0.01. In terms of profitability, DVA's ROE is -1.24%, compared to NIVFW's ROE of +0.33%. Regarding short-term risk, DVA is more volatile compared to NIVFW. This indicates higher risk in terms of short-term price fluctuations for DVA.Check NIVFW's competition here
Mobile-health Network Solutions Class A Ordinary Shares (NASDAQ: MNDR)
DVA vs MNDR Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, MNDR has a market cap of 36.9K. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while MNDR trades at $1.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas MNDR's P/E ratio is -0.04. In terms of profitability, DVA's ROE is -1.24%, compared to MNDR's ROE of -0.46%. Regarding short-term risk, DVA is less volatile compared to MNDR. This indicates lower risk in terms of short-term price fluctuations for DVA.Check MNDR's competition here
Talkspace, Inc. (NASDAQ: TALKW)
DVA vs TALKW Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, TALKW has a market cap of 33.5K. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while TALKW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas TALKW's P/E ratio is 0.00. In terms of profitability, DVA's ROE is -1.24%, compared to TALKW's ROE of +0.00%. Regarding short-term risk, DVA is less volatile compared to TALKW. This indicates lower risk in terms of short-term price fluctuations for DVA.Check TALKW's competition here
Skylight Health Group Inc. (NASDAQ: SLHGP)
DVA vs SLHGP Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, SLHGP has a market cap of 0. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while SLHGP trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas SLHGP's P/E ratio is -30.38. In terms of profitability, DVA's ROE is -1.24%, compared to SLHGP's ROE of -0.48%. Regarding short-term risk, DVA is more volatile compared to SLHGP. This indicates higher risk in terms of short-term price fluctuations for DVA.Check SLHGP's competition here
Hanger, Inc. (NYSE: HNGR)
DVA vs HNGR Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, HNGR has a market cap of 0. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while HNGR trades at $18.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas HNGR's P/E ratio is 19.71. In terms of profitability, DVA's ROE is -1.24%, compared to HNGR's ROE of +0.52%. Regarding short-term risk, DVA is more volatile compared to HNGR. This indicates higher risk in terms of short-term price fluctuations for DVA.Check HNGR's competition here
Almost Family Inc. (NASDAQ: AFAM)
DVA vs AFAM Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, AFAM has a market cap of 0. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while AFAM trades at $56.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas AFAM's P/E ratio is N/A. In terms of profitability, DVA's ROE is -1.24%, compared to AFAM's ROE of +0.06%. Regarding short-term risk, DVA is less volatile compared to AFAM. This indicates lower risk in terms of short-term price fluctuations for DVA.Check AFAM's competition here
SOC Telemed, Inc. (NASDAQ: TLMD)
DVA vs TLMD Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, TLMD has a market cap of 0. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while TLMD trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas TLMD's P/E ratio is -1.60. In terms of profitability, DVA's ROE is -1.24%, compared to TLMD's ROE of -0.46%. Regarding short-term risk, DVA is more volatile compared to TLMD. This indicates higher risk in terms of short-term price fluctuations for DVA.Check TLMD's competition here
New Frontier Health Corporation (NYSE: NFH)
DVA vs NFH Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, NFH has a market cap of 0. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while NFH trades at $11.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas NFH's P/E ratio is -19.75. In terms of profitability, DVA's ROE is -1.24%, compared to NFH's ROE of -0.06%. Regarding short-term risk, DVA is more volatile compared to NFH. This indicates higher risk in terms of short-term price fluctuations for DVA.Check NFH's competition here
Kindred Healthcare, Inc. (NYSE: KND)
DVA vs KND Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, KND has a market cap of 0. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while KND trades at $9.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas KND's P/E ratio is -1.14. In terms of profitability, DVA's ROE is -1.24%, compared to KND's ROE of -0.53%. Regarding short-term risk, DVA is more volatile compared to KND. This indicates higher risk in terms of short-term price fluctuations for DVA.Check KND's competition here
Diversicare Healthcare Services, Inc. (NASDAQ: DVCR)
DVA vs DVCR Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, DVCR has a market cap of 0. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while DVCR trades at $10.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas DVCR's P/E ratio is 28.34. In terms of profitability, DVA's ROE is -1.24%, compared to DVCR's ROE of -0.15%. Regarding short-term risk, DVA is more volatile compared to DVCR. This indicates higher risk in terms of short-term price fluctuations for DVA.Check DVCR's competition here
SOC Telemed, Inc. (NASDAQ: TLMDW)
DVA vs TLMDW Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, TLMDW has a market cap of 0. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while TLMDW trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas TLMDW's P/E ratio is N/A. In terms of profitability, DVA's ROE is -1.24%, compared to TLMDW's ROE of -0.46%. Regarding short-term risk, DVA is less volatile compared to TLMDW. This indicates lower risk in terms of short-term price fluctuations for DVA.Check TLMDW's competition here
ATI Physical Therapy, Inc. (NYSE: ATIP-WT)
DVA vs ATIP-WT Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, ATIP-WT has a market cap of 0. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while ATIP-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas ATIP-WT's P/E ratio is N/A. In terms of profitability, DVA's ROE is -1.24%, compared to ATIP-WT's ROE of +2.05%. Regarding short-term risk, DVA is less volatile compared to ATIP-WT. This indicates lower risk in terms of short-term price fluctuations for DVA.Check ATIP-WT's competition here
Tivity Health, Inc. (NASDAQ: TVTY)
DVA vs TVTY Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, TVTY has a market cap of 0. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while TVTY trades at $32.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas TVTY's P/E ratio is 19.06. In terms of profitability, DVA's ROE is -1.24%, compared to TVTY's ROE of +1.75%. Regarding short-term risk, DVA is more volatile compared to TVTY. This indicates higher risk in terms of short-term price fluctuations for DVA.Check TVTY's competition here
DocGo Inc. (NASDAQ: DCGOW)
DVA vs DCGOW Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, DCGOW has a market cap of 0. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while DCGOW trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas DCGOW's P/E ratio is N/A. In terms of profitability, DVA's ROE is -1.24%, compared to DCGOW's ROE of -1.16%. Regarding short-term risk, DVA is less volatile compared to DCGOW. This indicates lower risk in terms of short-term price fluctuations for DVA.Check DCGOW's competition here
Skylight Health Group Inc. (NASDAQ: SLHG)
DVA vs SLHG Comparison September 2026
DaVita Inc. (NYSE: DVA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 11.7B. In comparison, SLHG has a market cap of 0. Regarding current trading prices, DVA is priced at $182.00 on the NYSE, while SLHG trades at $0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 14.30, whereas SLHG's P/E ratio is -1.48. In terms of profitability, DVA's ROE is -1.24%, compared to SLHG's ROE of N/A. Regarding short-term risk, DVA is less volatile compared to SLHG. This indicates lower risk in terms of short-term price fluctuations for DVA.Check SLHG's competition here